|
|
| VGX
Pharmaceuticals Announces Management Promotions
|
| Blue
Bell, PA – October 18, 2006 – |
|
VGX Pharmaceuticals announced the promotion of Dr.
Bryan B. J. Kim to Senior Director, Corporate Development and the promotion
of Anthony Kim to Director, Investor Relations.
“Bryan has been providing invaluable service in all aspects of our
business, especially with VGX International, which plays an important
role in our strategy to become a global pharmaceutical company,”
said Dr. J. Joseph Kim, a CEO and President. “This promotion recognizes
the important role he has played in our Company’s growth and I am
confident that he will continue to be a key part of the overall success
of the Company.”
Dr. Kim joined the Company in 2005 as Director. In addition to his responsibilities
with VGX, Dr. Kim is also a Clinical Assistant Professor at University
of Pennsylvania, School of Dental Medicine where he has developed innovative
clinical programs and directed important research projects granted by
NIDH in microbiology and immunology. Dr. Kim holds a Bachelor of Arts
degree in Economics and a Bachelor of Science degree in Biological Science,
both from University of California at Irvine. He also holds a Doctor of
Dental Medicine degree from the University of Pennsylvania.
Anthony Kim joined the Company in 2005 as Associate Director. He has been
responsible for Investor Relations, addressing the needs of our diverse
group of investors for both VGX Pharmaceuticals and VGX International.
Mr. Kim has over 10 years of experience in the securities and banking
industry. Prior to joining the Company he led a financials services company
in which he assisted his clients in raising money from high net-worth
individuals and financial institutions. Mr. Kim holds Bachelor's Degree
in Economics from the University of Washington.
“Anthony has been instrumental in leading the Investor Relations
activity at our Company and his contributions to our operation have been
invaluable. I expect his role and contributions to our company to continue
to grow,” said Dr. Kim.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About
VGX Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2007 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
